These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 5796792)

  • 1. Mechanism of action of proteolytic enzymes in the plasminogen-plasmin system.
    Hakim AA; Chappelle MS
    Enzymologia; 1969 Jan; 36(1):1-24. PubMed ID: 5796792
    [No Abstract]   [Full Text] [Related]  

  • 2. Degradation of fibrinogen by proteolytic enzymes. I. Characterization and isolation of products and their relation to fibrinolytic states.
    Sanchez-Avalos J; Miller SP
    Thromb Diath Haemorrh; 1968 Jul; 19(3):499-515. PubMed ID: 4974324
    [No Abstract]   [Full Text] [Related]  

  • 3. [The state of prothrombin, plasminogen and fibrinogen in the newborn infant].
    Potron G; Droulle C; Behar C; Leroux B; Ledoyen MP; Mascre W
    Pathol Biol (Paris); 1975 Dec; 23 suppl():56-62. PubMed ID: 4759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrin-dependent activation of plasminogen by a proteolytic digest of streptokinase.
    Nakashima A; Okada T; Sugie I
    Blood Coagul Fibrinolysis; 1990 Aug; 1(3):279-84. PubMed ID: 2103312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots.
    Tran-Thang C; Kruithof EK; Bachmann F
    J Clin Invest; 1984 Dec; 74(6):2009-16. PubMed ID: 6210307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen assay by means of the lysis time method.
    Berg W; Korsan-Bengtsen K; Ygge J
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase.
    Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Wu DT; Refino CJ; Keyt BA; Bennett WF
    Thromb Haemost; 1996 Jun; 75(6):915-20. PubMed ID: 8822586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrolysis of L-histidine methyl ester. II. Activity of various proteolytic enzymes with special reference to activators of human plasminogen.
    Cole ER
    Thromb Diath Haemorrh; 1968 Jul; 19(3):334-45. PubMed ID: 4236821
    [No Abstract]   [Full Text] [Related]  

  • 9. [Enzymic and non-enzymic fibrinolysis during intravenous administration of trypsin].
    Umarova BA; Strukova SM; Kudriashov BA
    Vopr Med Khim; 1984; 30(2):95-100. PubMed ID: 6540008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease.
    Kim PY; Stewart RJ; Lipson SM; Nesheim ME
    J Thromb Haemost; 2007 Jun; 5(6):1250-6. PubMed ID: 17266698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of plasma, serum, thrombin, and plasmin toward synthetic trypsin substrates.
    Szczeklik E; Orlowski M; Szczeklik A; Narczewska B
    Thromb Diath Haemorrh; 1968 Mar; 19(1):99-106. PubMed ID: 4231461
    [No Abstract]   [Full Text] [Related]  

  • 12. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
    Lijnen HR; Soria J; Soria C; Collen D; Caen JP
    Thromb Haemost; 1984 Feb; 51(1):108-9. PubMed ID: 6539000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [On the nipiopharmacologic aspects of certain enzymes].
    Scano V; Garau A
    Minerva Nipiol; 1967; 17(6):363-7. PubMed ID: 4896195
    [No Abstract]   [Full Text] [Related]  

  • 15. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
    Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma.
    Verheijen JH; Mullaart E; Chang GT; Kluft C; Wijngaards G
    Thromb Haemost; 1982 Dec; 48(3):266-9. PubMed ID: 6891841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation.
    Sahni A; Baker CA; Sporn LA; Francis CW
    Thromb Haemost; 2000 May; 83(5):736-41. PubMed ID: 10823272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electrophoretic analysis on the proteolytic decomposition of of FSH preparations].
    Khalaf H; Neumann U; Rimpler M
    Dtsch Tierarztl Wochenschr; 1995 Oct; 102(10):396-9. PubMed ID: 8591740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the inhibition of proteolytic enzymes by serum. I. The mechanism of the inhibition of trypsin, plasmin, and chymotrypsin by serum using fibrin tagged with I131 as a substrate.
    SHULMAN NR
    J Exp Med; 1952 Jun; 95(6):571-91. PubMed ID: 14946321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.